Silicon nanoparticles deliver genes to mouse brains
Meeting the FDA standards for biomarker data
Dr. Haiying Grunenwald studies gene expression in single cells Improvements in speed, sample size, sample handling and real-time applications are breathing new vigor into polymerase chain reaction (PCR) a 20-year-old foundation technology in molecular biology.
An In Vitro Assay for the Quantitation of PARP Activity in Cell Extracts and for Determining the Efficacy of PARP InhibitorsJuly 13, 2005 8:28 am | Articles | Comments
By Leonard S. Bazar, PhD click the image to enlarge Figure 1. Colorimetric readout of PARP activity. Panel A illustrates the blue color and Panel B the yellow color that results from the addition of acid.
Broad patent portfolio expected in the US
Algorithm predicts the best sequence combination
Institutions embrace the opportunity
Works against appetite and fat
Service providers form a unique alliance
A new target of the inflammatory process
Signaling for Stem Cells By comparing two signaling networks, scientists, in a recent issue of
Nanostream has announced a fraction collector add-on to the Veloce micro parallel liquid chromatography system.
Second in-house drug approved in two years
Structural bioinformatics-based approach
Blocks anti-apoptotic family of proteins
Researcher Receives $1M for Smallpox Virus
Integrating genealogical, clinical, and genetic databases
Effective in Gleevec-resistant chronic phase patients
NIH finds Software for High-Throughput Screening
Structure may help fight multidrug resistance
Therapeutic made from recombinant DNA active in mice
Life scientists seeking the "big picture" are recognizing the value of cell imaging techniques. Automated cell imaging arose from the need for more sophisticated drug discovery tools, principally at pharmaceutical and biotech companies
The use of cell-based assays is crucial for understanding the efficacy, specificity, permeability, solubility, stability and mechanism of drug interaction with target cells
New siRNA service offers four siRNAs targeting a gene of choice designed using the HiPerformance algorithm licensed from Novartis Pharmaceuticals, and are provided with a guarantee that at least two of the four siRNAs will result in efficient knockdown.